semaglutide approval mash CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Semaglutide, a GLP-1R agonist, is

Developed by leading scientists, we designed a new molecule and combined this with our proprietary formulation into a daily tablet that supports appetite regulation, metabolism, and longevity.* Evolv GLP-1 uses our own proprietary, science-backed ingredient designed to naturally activate GLP-1, a hormone in the body, for extended periods

FDA Approval Process Branded drugs must undergo multi-year clinical trials, driving up the cost

The 72-hour stability window is the most underreported constraint

Clean, Transparent, and Vegan-Friendly: Optiwav Weight Loss 12-in-1 GLP-1 is crafted without gluten, sugar, dairy, soy, or artificial additives

"New agreements to secure additional vaccine candidates for COVID-19"

Further mechanistic studies were initiated investigating whether SAR425899 targets the GCGR including effects on energy expenditure and amino acid patterns